Literature DB >> 22710840

[Focal hyperhidrosis.Quality of life, socioeconomic importance and use of internal medicinal therapy].

B Rzany1, C Müller, M Hund.   

Abstract

Focal hyperhidrosis can have a substantial influence on the professional, physical, emotional and social life of those affected. This becomes clear when the results of quality of life studies and Health Service Research studies are reviewed, e.g. affected patients were prepared to contribute additional money for treatment of hyperhidrosis. The systemic therapy of focal hyperhidrosis with oral anticholinergic agents is a quite economical treatment strategy. These products can be administered continuously or sporadically. However, only good clinical date for the continous treatment exists. Focal hyperhidrosis is a disease which requires our full attention. It should be discussed whether e.g. QoL questionnaires should be used routinelly.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22710840     DOI: 10.1007/s00105-012-2331-1

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  23 in total

1.  Willingness-to-pay as a measure of benefits. Relevant questions in the context of public decisionmaking about health care programs.

Authors:  A Gafni
Journal:  Med Care       Date:  1991-12       Impact factor: 2.983

2.  Willingness-to-pay and patient-defined benefits in the treatment of hyperhidrosis: results from the first German health services research study in hyperhidrosis.

Authors:  C Müller; M Augustin
Journal:  Br J Dermatol       Date:  2013-02       Impact factor: 9.302

Review 3.  What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature.

Authors:  V Bronsard; C Paul; S Prey; E Puzenat; P-A Gourraud; S Aractingi; F Aubin; M Bagot; B Cribier; P Joly; D Jullien; M Le Maitre; M-A Richard-Lallemand; J-P Ortonne
Journal:  J Eur Acad Dermatol Venereol       Date:  2010-04       Impact factor: 6.166

4.  A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis.

Authors:  Nelson Wolosker; José Ribas Milanez de Campos; Paulo Kauffman; Pedro Puech-Leão
Journal:  J Vasc Surg       Date:  2012-02-16       Impact factor: 4.268

5.  [Prevalence of hyperhidrosis in a population treated by beta-blocker].

Authors:  I Figarella; P Tréchot; F Girard; A Barbaud; E Aliot; J L Schmutz
Journal:  Ann Dermatol Venereol       Date:  2001-09       Impact factor: 0.777

6.  Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

Authors:  A Y Finlay; G K Khan
Journal:  Clin Exp Dermatol       Date:  1994-05       Impact factor: 3.470

7.  [Effect of bornaprine in localized hyperhidrosis].

Authors:  A Castells Rodellas; M Moragón Gordon; A Ramírez Bosca
Journal:  Med Cutan Ibero Lat Am       Date:  1987

8.  Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial.

Authors:  M K Naumann; H Hamm; N J Lowe
Journal:  Br J Dermatol       Date:  2002-12       Impact factor: 9.302

Review 9.  Long-term results and quality-of-life measures in the management of hyperhidrosis.

Authors:  Ibrahim B Cetindag; Theresa M Boley; Kelli N Webb; Stephen R Hazelrigg
Journal:  Thorac Surg Clin       Date:  2008-05       Impact factor: 1.750

10.  Definition of treatment goals for moderate to severe psoriasis: a European consensus.

Authors:  U Mrowietz; K Kragballe; K Reich; P Spuls; C E M Griffiths; A Nast; J Franke; C Antoniou; P Arenberger; F Balieva; M Bylaite; O Correia; E Daudén; P Gisondi; L Iversen; L Kemény; M Lahfa; T Nijsten; T Rantanen; A Reich; T Rosenbach; S Segaert; C Smith; T Talme; B Volc-Platzer; N Yawalkar
Journal:  Arch Dermatol Res       Date:  2010-09-21       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.